Tumour photosensitizers: Approaches to enhance the selectivity and efficiency of photodynamic therapy

Journal of Photochemistry and Photobiology B: Biology

Volumn 36, Issue 2, 1996, Pages 87-93

  Jori, Giulio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Photofrin; Tumour photosensitizers

Indexed keywords

ALBUMIN; BENZOPORPHYRIN DERIVATIVE; CREMOPHOR; EPIDERMAL GROWTH FACTOR; ETIOPURPURIN; LIPOSOME; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; TALAPORFIN; TETRAHYDROXYPHENYLCHLORIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CONFERENCE PAPER; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG TUMOR LEVEL; DRUG UPTAKE; LIGHT ABSORPTION; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUMOR NECROSIS;

ANTINEOPLASTIC AGENTS; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0030294849     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1011-1344(96)07352-6     Document Type: Conference Paper

References (42)

1. [1] A. M. Richter, R.K. Chowdhary, L. Ratkay, A.K. Jain, A.J. Canaan, H. Meadows, M. Obochi, D. Waterfield and J.G. Levy, Nononcologic potentials for photodynamic therapy, Proc. SPIE, 2078 (1994) 293-304.
2. [2] C.J. Gomer, Photodynamic therapy in the treatment of malignancies, Sem. Hematol., 26 (1989) 27-34.
3. [3] C. Zhou, Mechanisms of tumor necrosis induced by photodynamic therapy, J. Photochem. Photobiol., B:Biol., 3 (1989) 299-318.
4. [4] T.J. Dougherty, Photosensitizers: therapy and detection of malignant tumors, Photochem. Photobiol., 45 (1987) 879-889.
5. [5] D.A. Bellnier and B.W. Henderson, Determinants for photodynamic tissue destruction, in B.W. Henderson and T.J. Dougherty (eds.), Photodynamic Therapy. Basic Principles and Clinical Applications, Marcel-Dekker, New York, 1992, pp. 117-128.
6. [6] J.G. Levy, E. Waterfield, A.M. Richter, C. Smith, H. Lui, L. Hruza, R.R. Anderson and V. Salvatori, Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A, Proc. SPIE, 2078 (1994) 91-101.
7. [7] J.S. Nelson, W.G. Roberts and M.W. Berns, In vivo studies on the utilization of mono-L-aspartyl-chlorin e6 for photodynamic therapy, Cancer Res., 47 (1987) 4681-4685.
8. [8] H.B. Ris, H.J. Altermatt, R. Inderbitzi, R. Hess, B. Nachbur, J.C.M. Stewart, Q. Wang, C.K. Lim, R. Bonnett, M.C. Berenbaum and U. Althaus, Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results, Br. J. Cancer, 64 (1991) 1116-1120.
9. [9] S.H. Selman, G.M. Garbo, R.W. Keck, M. Kreimer-Birnbaum and A.R. Morgan, A dose response analysis of purpurin derivatives used as photosensitizers for the photodynamic treatment of transplantable urothelial tumours, J. Urol., 137 (1987) 1255-1257.
10. [10] K. Schieweck, H.-G. Capraro, U. Isele, P. van Hoogevest, M. Ochsner, T. Maurer and E. Batt, CGP 55 847, liposome-delivered zinc(II)-phthalocyanine as a phototherapeutic agent for tumors, Proc. SPIE, 2078 (1994) 107-118.
11. [11] G. Jori and E. Reddi, Second generation photosensitizers for the photodynamic therapy of tumours, in R.H. Douglas, J. Moan and G. Rontò (eds.), Light in Biology and Medicine, Vol. 2, Plenum, London, 1991, pp. 253-266.
12. [12] D. Kessel, Determinants of hematoporphyrin-catalyzed photosensitization, Photochem. Photobiol., 36 (1982) 99-101.
13. [13] J. Moan, K. Berg, H.B. Steen, T. Warloe and K. Madslien, Fluorescence and photodynamic effects of phthalocyanines and porphyrins in cells, in B.W. Henderson and T.J. Dougherty (eds.), Photodynamic Therapy. Basic Principles and Clinical Applications, Marcel-Dekker, New York, 1992, pp. 19-36.
14. [14] G. Jori, Low density lipoproteins-liposome delivery systems for tumour photosensitizers in vivo, in B.W. Henderson and T.J. Dougherty (eds.), Photodynamic Therapy. Basic Principles and Clinical Applications, Marcel-Dekker, New York, 1992, pp. 173-186.
15. [15] D. Mew, C.K. Wat, G.H.N. Towers and J.G. Levy, Photoimmunotherapy: treatment of animal tumours with tumor-specific monoclonal antibody-hematoporphyrin conjugates, J. Immunol., 130 (1983) 1473-1477.
16. [16] T. Hasan, Photosensitizer delivery mediated by macromolecular carrier systems, in B.W. Henderson and T.J. Dougherty (eds.), Photodynamic Therapy. Basic Principles and Clinical Applications, Marcel-Dekker, New York, 1992, pp. 187-200.
17. [17] G. Jori and J.D. Spikes, Photobiochemistry of porphyrins, in K.C. Smith (ed.), Topics in Photomedicine, Plenum, New York, 1983, pp. 183-319.
18. [18] E. Reddi and G. Jori, Steady-state and time-esolved spectroscopic studies of photodynamic sensitizers: porphyrins and phthalocyanines, Rev. Chem. Interm., 10 (1988) 241-268.
19. [19] G. Jori, Molecular and cellular mechanisms in photomedicine: porphyrins in microheterogeneous environments, in R.V. Bensasson, G. Jori, E. Land and T.G. Truscott (eds.), Primary Photoprocesses in Biology and Medicine, Plenum Press, New York, 1985, pp. 349-355.
20. [20] J.D. Spikes, Phthalocyanines as photosensitizers in biological systems and for the photodynamic therapy of tumours, Photochem. Photobiol., 43 (1986) 691-699.
21. [21] E. Ben-Hur, Photochemistry and photobiology of phthalocyanines: new sensitizers for photodynamic therapy of cancer, in A. Favre, R. Tyrrell and J. Cadet (eds.), From Photophysics to Photobiology, Elsevier Science Publisher, New York, 1987, pp. 407-420.
22. [22] B.D. Rihter, M.D. Bohorquez, M.A.J. Rodgers and M.E. Kenney, Two new sterically hindered phthalocyanines: synthetic and photodynamic aspects, Photochem. Photobiol., 55 (1992) 677-680.
23. [23] L.O. Svaasand, E. Martinelli, C.J. Gomer and A.E. Profio, Optical characteristics of intraocular tumours in the visible and near-infrared., Proc. SPIE, 1203 (1990) 2-21.
24. [24] R. Biolo, G. Jori, M. Soncin, R. Pratesi, U. Vanni, B. Rihter, M.E. Kenney and M.A J. Rodgers, Photodynamic therapy of B16 pigmented melanoma with liposome-delivered Si(IV)-naphthalocyanine, Photochem. Photobiol., 59 (1994) 362-365.
25. [25] G. Jori, Far-red absorbing photosensitizers: their use in the photodynamic therapy of tumours, J. Photochem. Photobiol., A:Chem., 62 (1992) 371-378.
26. [26] R. Bonnett and M. Berenbaum, Porphyrins as photosensitizers, in G. Bock and S. Harnett (eds.) Photosensitizing Compounds: their Chemistry, Biology and Clinical Use (Ciba Foundation Symposium 146), J. Wiley, Chichester, 1989, pp. 40-59.
27. [27] B.D. Rihter, M.E. Kenney, W.E. Ford and M.A.J. Rodgers, Photodynamic reactions involving Pd(II)-octabutoxy-naphthalocyanine and molecular oxygen, J. Am. Chem. Soc., 115 (1993) 8146-8152.
28. [28] G. Jori and E. Reddi, Photochemotherapy of tumours: molecular and biophysical bases., in R. Pratesi (ed.) Optronic Techniques in Diagnostic and Therapeutic Medicine, Plenum, New York, 1991, pp. 227-236.
29. [29] J.W. Winkelman, Quantitative studies on tetraphenylporphine-sulfonate and hematoporphyrin derivative, in D. Kessel (ed.) Methods in Porphyrin Photosensitization, Vol. 193, Plenum, New York, 1985, pp. 91-102.
30. [30] G. Jori, Factors controlling the selectivity and efficiency of tumour damage in photodynamic therapy, Lasers Med. Sci., 5 (1990) 115-120.
31. [31] S.G. Bown, Photodynamic therapy to scientists and clinicians: one world or two?, J. Photochem. Photobiol., B:Biol., 6 (1990) 1-12.
32. [32] B.C. Wilson and M.S. Patterson, Physics of photodynamic therapy, Phys. Med. Biol., 31 (1986) 327-360.
33. [33] H. Barr, N. Krasner, P.B. Boulos, P. Chatlani and S.G. Bown, Photodynamic therapy for colorectal cancer: a quantitative pilot study, Br. J. Surg., 77 (1990) 93-96.
34. [34] A.R. Oseroff, Cationic sensitizers, combination therapies, and new methodologies, in B.W. Henderson and T.J. Dougherty (eds.), Photodynamic Therapy. Basic Principles and Clinical Applications, Marcel-Dekker Inc., New York, 1992, pp. 79-96.
35. [35] C.J. Tralau, H. Barr, A.J. MacRobert and S.G, Bown, Relative merits of porphyrin and phthalocyanine sensitization for photodynamic therapy, in D. Kessel (ed.), Photodynamic Therapy of Neoplastic Disease, Vol. I, CRC, Boca Raton, 1990, pp. 263-278.
36. [36] A.J. MacRobert, S.G. Bown and D. Phillips, What are the ideal photoproperties for a sensitizer?, in G. Bock and S. Harnett (eds.) Photosensitizing Compounds: their Chemistry, Biology and Clinical Use (Ciba Foundation Symposium 146), J. Wiley, Chichester, 1989, pp. 4-16.
37. [37] G. Jori, Photodynamic therapy: a novel approach to the treatment of tumours, Bull. Mol. Biol. Med., 15 (1990) 73-83.
38. [38] D. Kessel, HPD: structure and determinants of localization, in D. Kessel (ed.) Photodynamic Therapy of Neoplastic Disease, CRC, Boca Raton, 1990, pp. 1-14.
39. [39] M. Korbelik, G. Krosl and D.J. Chaplin, Photofrin uptake by murine macrophages, Cancer Res., 51 (1991) 2251-2255.
40. [40] C. Candide, P. Morlière, J.C. Maziere, S. Goldstein, R. Santus, L. Dubertret, J.P. Reyftmann and J. Polnowski, In vitro interaction of the photoactive anticancer porphyrin derivative Photofrin II with low density lipoproteins and its delivery to cultured fibroblasts, FEBS Lett., 207 (1986) 133-138.
41. [41] F. Ricchelli, S. Gobbo, G. Jori, G, Moreno, F. Vinzens and C. Salet, Photosensitization of mitochondria by liposome-bound porphyrins, Photochem. Photobiol., 58 (1993) 53-58.
42. [42] L.C. Penning, J.W.M, Lagerberg, J.H. VanDierendonck, C.J. Cornelisse, T.M.A.R. Dubbelman and J. Van Steveninck, The role of DNA damage and inhibition of poly(ADP-ribosyl)ation in loss of clonogenicity of murine L929 fibroblasts, caused by photodynamically induced oxidative stress, Cancer Res., 54 (1994) 5561-5567.